Table 3.
Clinical characteristics and pathological changes in the livers of 70 NASH patients
| Paramter | NASH | ||
|---|---|---|---|
| ANA(−) (n = 36) | ANA(+) (n = 20) | AIH-overlap (n = 14) | |
| IAIHG score | |||
| ≥ 15 (definite AIH) | 0 (0%) | 0 (0%) | 14 (100%) ††‡‡ |
| 10–15 (probable AIH) | 13 (36.1%) | 20 (100%) | 0 (0%) |
| < 10 | 23 (63.9%) | 0 (0%) | 0 (0%) |
| Age (years) | 51.5 (40.8–66.3) | 58.5 (53.3–67.3) | 59 (39.8–68.5) |
| Male sex (%) | 58.3 | 25 † | 14.3 † |
| BMI (kg/m2) | 28.7 (25.8–31.5) | 28.2 (23.9–32.2) | 26.9 (23.6–30.3) |
| Albumin (g/dL) | 4.2 (3.7–4.5) | 4.1 (4.0–4.2) | 4.0 (3.8–4.4) |
| AST (U/L) | 46 (36.5–70.5) | 51.5 (42.8–77.3) | 82 (59–87.3) † |
| ALT (U/L) | 68.5 (47.5–108.3) | 70.5 (47.5–126.0) | 66 (64.5–90.5) |
| GGT (U/L) | 58 (41.8–80.5) | 59 (34.0–88.5) | 61.5 (41.8–138.8) |
| Total bilirubin (mg/dL) | 0.75 (0.60–1.00) | 0.8 (0.70–1.10) | 0.85 (0.68–0.93) |
| HDL-C (mg/dL) | 46.0 (40.4–53.5) | 57.7 (47.6–69.5) † | 53.8 (49.0–58.5) |
| LDL-C (mg/dL) | 119 (97–135) | 109.5 (95.0–127.3) | 100.5 (88.0–153.0) |
| Triglycerides (mg/dL) | 116 (90.5–175.0) | 103 (74.3–134.8) | 117 (110.5–127.3) |
| Creatinine (mg/dL) | 0.72 (0.56–0.87) | 0.69 (0.57–0.81) | 0.57 (0.56–0.60) |
| CRP (mg/dL) | 0.12 (0.10–0.28) | 0.10 (0.07–0.26) | 0.12 (0.07–0.51) |
| Platelet count (10,000/µl) | 21.6 (17.3–28.0) | 21.1 (20.1–27.7) | 15.6 (14.4–20.7) |
| Prothrombin time (%) | 100 (94.5–100.0) | 100 (100–100) | 100 (100–100) |
| FBG (mg/dL) | 97 (86.3–115.5) | 98 (86.5–107.5) | 91 (81.0–104.5) |
| HbA1c (N) | 6.1 (5.6–7.2) | 6.1 (5.9–6.9) | 6 (5.5–6.1) |
| ANA | |||
| Negative (%) | 36 (100%) | 0 (0%) †† | 2 (14.2%) †† |
| Positive (%) | 0 (0%) | 20 (100%) | 12 (85.8%) |
| ≧ 1:40 (%) | 0 (0%) | 17 (85%) | 5 (41.7%) |
| ≧ 1:320 (%) | 0 (0%) | 3 (15%) | 4 (33.3%) |
| ≧ 1:2560 (%) | 0 (0%) | 0 (0%) | 3 (25%) |
| AMA-M2 (index) | 0.55 (0.50–0.95) | 1.4 (0.8–1.7) † | 1.7 (1.65–2.20) ††‡ |
| IgA (mg/dL) | 230.5 (202.0–306.5) | 280.5 (233.0–356.3) | 255 (214.5–451.5) |
| IgG (mg/dL) | 1189 (1049.0–1338.5) | 1360 (1159.0–1575.5) † | 1611 (1429.8–1922.3) †† |
| IgM (mg/dL) | 80.5 (57.8–111.0) | 93 (58.3–139.3) | 133 (121.8–153.0) ††‡ |
| Hyaluronic acid (ng/mL) | 37.5 (11.9–60.1) | 50.2 (26.4–82.1) | 109.8 (66.1–152.0) † |
| Liver Stiffness (kPa) | 10.2 (8.5–13.2) | 8.1 (6.8–10.3) | 10 (6.2–15.9) |
| CAP (dB/m) | 306.5 (274.8–338.5) | 313.5 (273.3–342.0) | 257 (203.8–319.5) †‡ |
| NAS | |||
| Steatosis | |||
| 0 | 0 (0%) | 0 (0%) | 0 (0%) †‡ |
| 1 | 18 (50%) | 8 (40%) | 10 (71.4%) |
| 2 | 11 (30.6%) | 10 (50%) | 4 (28.6%) |
| 3 | 7 (19.4%) | 2 (10%) | 0 (0%) |
| Lobular inflammation | |||
| 0 | 1 (2.8%) | 0 (0%) | 0 (0%) |
| 1 | 19 (52.7%) | 10 (50%) | 5 (35.7%) |
| 2 | 15 (41.7%) | 10 (50%) | 9 (64.3%) |
| 3 | 1 (2.8%) | 0 (0%) | 0 (0%) |
| Ballooning | |||
| 0 | 0 (0%) | 0 (0%) | 0 (0%) |
| 1 | 26 (72.2%) | 15 (75%) | 8 (57.1%) |
| 2 | 10 (27.8%) | 5 (25%) | 6 (42.9%) |
| Fibrosis | |||
| 0 | 0 (0%) | 2 (10%) | 0 (0%) ‡ |
| 1 | 17 (47.2%) | 9 (45%) | 1 (7.2%) |
| 1A | 13 (76.5%) | 4 (20%) | 0 (0%) |
| 1B | 4 (23.5%) | 5 (25%) | 1 (7.2%) |
| 1C | 0 (0%) | 0 (0%) | 0 (0%) |
| 2 | 5 (13.9%) | 6 (30%) | 3 (21.4%) |
| 3 | 11 (30.6%) | 3 (15%) | 10 (71.4%) |
| 4 | 3 (8.3%) | 0 (0%) | 0 (0%) |
Bold values indicate the parameter significantly changes between AIH-overlap and ANA -/+ NASH patients
†p < 0.05 compared with ANA(−), ††p < 0.001 compared with ANA(-)
‡p < 0.05 AIH-overlap compared with ANA( +), ‡‡p < 0.001 AIH-overlap compared with ANA( +)
Values are presented as N, N (%), or median (P25–P75)